About Genenta Science
Genenta Science is a publicly listed company based in Milan (Italy) founded in 2014 by Pierluigi Paracchi. Lentivirus-based gene and cell therapies for cancer are developed. Genenta Science has raised $33.58 million across 4 funding rounds from investors including Mediobanca Private Banking, ENEA Tech e Biomedical and Qianzhan. The company has 13 employees. Its chief executive, as recorded, is Pierluigi Paracchi. Genenta Science offers products and services including Temferonâ„¢. Its focus areas include Life Sciences, Gene Therapy, DNA and dsDNA.
Company details
Genenta Science was founded in 2014 in Milan, Italy, with operations centered on biotechnology. Lentivirus-based gene and cell therapies are developed for cancer treatment, targeting solid tumors, hematological malignancies, and glioblastoma. The lead candidate, Temferon, is utilized as a hematopoietic stem progenitor cell immuno-gene therapy. Tie2-expressing monocytes are also employed in immunotherapies for various cancers. Focus is maintained on advancing these therapies through clinical development.
- Headquarters Milan, Italy
- Employees 13
- Founders Pierluigi Paracchi
- Stage Public
- SectorsHealthcare
- Website genenta.com
- Social LinkedIn X
- Legal Name Genenta Science Spa Sponsored Adr
- Net Profit-$7.37 M (USD)23.56as on Dec 31, 2025
- EBITDA-$7.42 M (USD)29.42as on Dec 31, 2025
- Total Equity Funding$33.58M (USD)
in 4 rounds
- Latest Funding Round$21.9M (USD), Post-IPO
Mar 2025
- InvestorsMediobanca Private Banking
& 2 more
- Employee Count13
Products & Services of Genenta Science
Genenta Science offers a comprehensive portfolio of products and services, including Temferon™.
Delivers therapeutic payloads to tumor microenvironment for cancer treatment.
Funding Insights of Genenta Science
Genenta Science has successfully raised a total of $33.58M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21.9 million completed in March 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $33.58M
- Total Rounds 4
- Last Round Post-IPO — $21.9M
- First Round $11M
(Mar 2015)
- Investors Count 3
All 4 funding rounds of Genenta Science with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2025 | $21.9M | Post-IPO | – | – | |
| Sep 2019 | $14.58M | Series C | – | Qianzhan | – |
| Sep 2017 | $8M | Series B | – | – | – |
| Mar 2015 | $11M | Series A | – | Mediobanca | – |
3 investors in total: 3 institutional.
Investors in Genenta Science
Genenta Science has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Mediobanca Private Banking, ENEA Tech e Biomedical and Qianzhan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| eneatechbiomedical.it | ||||
Industry trends and market analysis are provided by Qianzhan. | 1998 | qianzhan.com | Shenzhen, China | |
Mediobanca Private Banking is focused on wealth management and investment banking. | 1946 | mediobancapb.com | Milan, Italy |
Investor details for Genenta Science
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genenta Science
13 people are tracked at Genenta Science (7 in leadership, 4 in board & advisors, 2 in team); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
Pierluigi Paracchi | Co-Founder & CEO | Leadership |
Richard B. Slansky | CFO | Leadership |
Carlo Russo | Chief Medical Officer & Head, Development | Leadership |
Barbara Regonini | Finance Director | Leadership |
Stefania Mazzoleni | Director Of Program Development | Leadership |
Gianfranco de Nigris | Vice President Corporate Development | Leadership |
Barbara R. | Director Of Finance | Leadership |
Mark A. Sirgo | Chairman | Board & advisors |
Antony Marucci | Director | Board & advisors |
Guido Guidi | Director | Board & advisors |
Roger Abravanel | Director | Board & advisors |
Valentina Brambilla | Clinical Project Manager | Team |
Capotondo Alessia | Clinical Project Manager And Clinical Scientist | Team |
Complete people profiles for Genenta Science
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Genenta Science
Genenta Science is a publicly listed company on the NASDAQ with ticker symbol GNTA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Dec 2021
- Listed onNASDAQ: GNTA
- Listed entityGenenta Science SpA Sponsored ADR
- Exchange sectorHealth technology
- ISINUS36870W1009
- Share price$0.72 (-4.99% on the day) · 2026-10-13
- Market capitalisation$34.8M
- Volume (last session)34,282
Financials of Genenta Science
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$7.4M | -$7.4M | |
| 2024 | -$9.6M | -$10.5M | |
| 2023 | -$12.6M | -$12.6M | |
| 2022 | -$8.9M | -$11.6M | |
| 2021 | -$6.5M | -$6.7M |
Detailed financial statements for Genenta Science
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Genenta Science
4 dated milestones of Genenta Science across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Genenta Science is founded.
- Funding First funding round of $11.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $21.9M.
Web traffic of Genenta Science
The website of Genenta Science (genenta.com) receives about 3.7K visits a month.
- Monthly visits3.7K
▲ 81% vs previous month
Websites whose visitors overlap most with Genenta Science. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
google.it | google.it | 100% | – | ||
| novacell.com | 76% | 1.9K | #8,657,904 | View details | |
krka.it | krka.it | 72% | #8,562,208 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genenta Science
Complete news archive for Genenta Science
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genenta Science
Genenta Science was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Genenta Science is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
Pierluigi Paracchi is the CEO of Genenta Science, as recorded in our data. They have also founded this company.
Genenta Science is a funded company, having raised a total of $33.58M across 4 funding rounds to date. The company's 1st funding round was a Series A of $11M, raised on Mar 2015.
Genenta Science has 13 employees.
Genenta Science was founded in 2014 in Milan, Italy, with operations centered on biotechnology. Lentivirus-based gene and cell therapies are developed for cancer treatment, targeting solid tumors, hematological malignancies, and glioblastoma. The lead candidate, Temferon, is utilized as a hematopoietic stem progenitor cell immuno-gene therapy. Tie2-expressing monocytes are also employed in immunotherapies for various cancers. Focus is maintained on advancing these therapies through clinical development.
Genenta Science offers Temferonâ„¢.
Yes, Genenta Science is publicly traded on NASDAQ under the ticker symbol GNTA.
Genenta Science has 3 investors. Key investors include Mediobanca Private Banking, ENEA Tech e Biomedical, and Qianzhan.
Genenta Science operates through Genenta Science.